Anthem Biosciences Ltd releases revised unaudited Q2 FY2026 results
The company filed a revised press release on its unaudited financial results for the quarter ended 30 June 2026 on 21 July 2026.
What Anthem Biosciences announced
Anthem Biosciences Ltd filed a revised press release on 21 July 2026, providing its unaudited financial results for the quarter ended 30 June 2026. The filing was made under Regulation 30 (Listing Obligations and Disclosure Requirements) and is available on the BSE portal.
"Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026" (BSE filing, 21 July 2026).
The company indicated that the revision supersedes any earlier interim communication for the same period, but no quantitative financial data were included in the excerpt provided.
Revised press release details
The filing is labelled as a "Press Release / Media Release (Revised)" and is classified as a Regulation 30 announcement. It confirms that the results are unaudited, meaning they have not yet been examined by independent auditors and are subject to change upon final audit.
No specific numbers—such as revenue, operating profit, net loss, or earnings per share—were disclosed in the document. Consequently, investors cannot assess performance trends from this filing alone.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Anthem Biosciences Ltd |
| BSE Scrip Code | 544449 |
| Filing date | 21 July 2026 (13:55:08 GMT) |
| Announcement type | Revised press release (Regulation 30) |
| Period covered | Quarter ended 30 June 2026 |
| Audit status | Unaudited |
| Financial figures disclosed | None in the filing |
| Source | BSE (PDF link) |
Why this matters for investors
The revision signals that the company wishes to update the market on its interim performance, albeit without providing the underlying numbers. For shareholders, the unaudited nature of the results means that any figures, once audited, could differ materially. The absence of disclosed financial metrics limits immediate analysis of revenue growth, profitability, or cash‑flow health. However, the filing satisfies regulatory disclosure requirements, ensuring that the market is aware a revised interim update exists.
Conclusion
Anthem Biosciences Ltd has submitted a revised, unaudited interim results press release for Q2 FY2026 on 21 July 2026. While the filing fulfills its regulatory obligations, it does not reveal any quantitative performance data, leaving investors to await the audited results or a more detailed subsequent release for substantive financial insight.
Frequently asked questions
Related stocks
Source filing: view original